{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:36:05Z","timestamp":1791408965534,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ygyno.2012.05.006","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T16:30:56Z","timestamp":1337185856000},"page":"448-454","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of ERCC1\/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum"],"prefix":"10.1016","volume":"126","author":[{"given":"Julie A.","family":"DeLoia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil R.","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Strange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunquio","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Nuttall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Niedernhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2012.05.006_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1525-1438.2007.01098.x","article-title":"Timing of debulking surgery in advanced ovarian cancer","volume":"18","author":"Vergote","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0010","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.6.15.2719","article-title":"Docetaxel in ovarian cancer","volume":"6","author":"Escobar","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0025","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.lungcan.2010.08.022","article-title":"Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC","volume":"71","author":"Chang","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-4020-5133-3_11","article-title":"Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract","volume":"587","author":"Hofler","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0921-8777(01)00092-1","article-title":"Repair of DNA interstrand cross-links","volume":"486","author":"Dronkert","year":"2001","journal-title":"Mutat Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0055","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0060","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)80155-5","article-title":"Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease","volume":"86","author":"Sijbers","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","article-title":"Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance","volume":"2","author":"McHugh","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0070","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","article-title":"The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks","volume":"24","author":"Niedernhofer","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ygyno.2010.01.048","article-title":"Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies","volume":"117","author":"Darcy","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2009.01.002","article-title":"Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study","volume":"113","author":"Kim","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0085","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1200\/JCO.2008.16.1323","article-title":"Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer","volume":"26","author":"Krivak","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000100008","article-title":"The C19007T polymorphism of ERCC1 and its correlation with the risk of epithelial ovarian and endometrial cancer in Korean women. A case control study","volume":"64","author":"Jo","year":"2007","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/emm.2006.38","article-title":"Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer","volume":"38","author":"Kang","year":"2006","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0100","article-title":"Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression","volume":"47","author":"Li","year":"2001","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0105","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/0008-5472.CAN-06-4076","article-title":"A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy","volume":"67","author":"Darcy","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejca.2008.12.013","article-title":"A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0115","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ijc.23987","article-title":"The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer","volume":"124","author":"Weberpals","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0120","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/jnci\/84.19.1512","article-title":"ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients","volume":"84","author":"Dabholkar","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI117388","article-title":"Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy","volume":"94","author":"Dabholkar","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/gyno.1996.4609","article-title":"Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer","volume":"65","author":"Codegoni","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0135","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1525-1438.2007.01155.x","article-title":"Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer","volume":"18","author":"Lin","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0140","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMc070742","article-title":"ERCC1 and non-small-cell lung cancer","volume":"356","author":"Niedernhofer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0145","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/0008-5472.CAN-09-1237","article-title":"Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue","volume":"69","author":"Bhagwat","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1086\/512486","article-title":"First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure","volume":"80","author":"Jaspers","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nature05456","article-title":"A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis","volume":"444","author":"Niedernhofer","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0160","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1002\/j.1460-2075.1993.tb06043.x","article-title":"Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro","volume":"12","author":"Biggerstaff","year":"1993","journal-title":"EMBO J"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/mutage\/12.1.41","article-title":"A low content of ERCC1 and a 120 kDa protein is a frequent feature of group F xeroderma pigmentosum fibroblast cells","volume":"12","author":"Yagi","year":"1997","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0170","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1128\/MCB.24.3.1200-1205.2004","article-title":"Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF","volume":"24","author":"Tian","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1383-5726(97)00004-6","article-title":"A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues","volume":"382","author":"Yu","year":"1997","journal-title":"Mutat Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.coph.2006.01.011","article-title":"Predicting the outcome of chemotherapy for lung cancer","volume":"6","author":"Rosell","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0185","doi-asserted-by":"crossref","first-page":"23419","DOI":"10.1074\/jbc.273.36.23419","article-title":"Cisplatin induction of ERCC-1 mRNA expression in A2780\/CP70 human ovarian cancer cells","volume":"273","author":"Li","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0190","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/0008-5472.CAN-04-0348","article-title":"Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents","volume":"64","author":"Youn","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0195","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1158\/0008-5472.CAN-08-3363","article-title":"Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells","volume":"69","author":"Fan","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.05.006_bb0200","first-page":"793","article-title":"Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes","volume":"48","author":"Sklar","year":"1988","journal-title":"Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T20:25:41Z","timestamp":1561753541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090825812003502"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.05.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}